0001140361-24-008358.txt : 20240216
0001140361-24-008358.hdr.sgml : 20240216
20240216160549
ACCESSION NUMBER: 0001140361-24-008358
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240214
FILED AS OF DATE: 20240216
DATE AS OF CHANGE: 20240216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Patel Kinnari
CENTRAL INDEX KEY: 0001725929
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36829
FILM NUMBER: 24648334
MAIL ADDRESS:
STREET 1: 430 EAST 29TH STREET
STREET 2: SUITE 1040
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ROCKET PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001281895
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
BUSINESS PHONE: 646-440-9100
MAIL ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
FORMER COMPANY:
FORMER CONFORMED NAME: INOTEK PHARMACEUTICALS CORP
DATE OF NAME CHANGE: 20040226
4
1
form4.xml
FORM 4
X0508
4
2024-02-14
0001281895
ROCKET PHARMACEUTICALS, INC.
RCKT
0001725929
Patel Kinnari
C/O ROCKET PHARMACEUTICALS, INC.
9 CEDARBROOK DRIVE
CRANBURY
NJ
08512
true
See Remarks
false
Common Stock
2024-02-14
4
M
0
26189
0
A
245478
D
Common Stock
5675
I
By Spouse
Common Stock
101594
I
By Adaptive Technology LLC
Restricted Stock Units
2024-02-14
4
M
0
3990
0
D
Common Stock
3990
15960
D
Restricted Stock Units
2024-02-14
4
M
0
22199
0
D
Common Stock
22199
44268
D
Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award.
The shares are held indirectly through Adaptive Technology, LLC, a limited liability company that is owned and managed by the reporting person's husband.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal annual installments over the following two years.
One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal annual installments over the following two years.
President & Chief Operating Officer
/s/ Martin Wilson, as attorney-in-fact for Kinnari Patel
2024-02-16